Resources

Real-World Experience That Informs Investment Value

PharmaKonsult draws on decades of pharmaceutical leadership experience to evaluate the assumptions that influence drug asset value. Our case studies demonstrate how competitive differentiation, physician adoption, reimbursement, and strategic decisions can affect a therapy's market potential and future licensing attractiveness.

8 September 2026 · Portfolio Strategy · Commercial Due Diligence · Neuroscience

Independent Portfolio Assessment — Anavex Life Sciences

Independent assessment of Anavex’s four clinical programs—integrating development risk, investment, competition and commercial opportunity into an actionable portfolio strategy.

Read Case Study
7 September 2026 · Institutional Markets · Market Access · Commercial Strategy

When Product Demand Is Not Enough

Restored formulary access at a military institution by reframing a demand problem as an institutional commercialization challenge—and engaging the stakeholders who could reverse the decision.

Read Case Study
3 September 2026 · Product Launch · Commercial Leadership · Specialty Neurology

Leading a Nationally Successful Launch During COVID-19

Led a newly hired team through a remote XCOPRI launch during COVID-19—building account management, solving patient-access barriers and achieving #1 national launch performance.

Read Case Study
3 September 2026 · Market Access · Reimbursement · Commercial Execution

Turning a Market Access Barrier into Commercial Growth

Identified an FEP reimbursement barrier in Washington, DC, collaborated with Market Access to improve formulary access and helped approximately double territory sales—with All-Star recognition for three consecutive years.

Read Case Study
3 September 2026 · Market Access · Institutional Markets · Commercial Execution

Removing an Institutional Purchasing Barrier

Identified an institutional VA purchasing barrier, escalated through the VISN structure and helped contribute to approximately 250% regional sales growth.

Read Case Study
24 August 2026 · Pharmaceutical Commercialization · Market Analysis · HEOR

When Clinical Results Don't Drive Adoption

When strong clinical evidence does not produce expected adoption, look beyond the trial—examine non-adopters, treatment pathways and the broader competitive environment.

Read Case Study